{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910794531603321"]
[null,null,"Autore",null,"Mittal Neeraj"]
[null,null,"Titolo",null,"COVID-19"]
[null,null,"Pubbl/distr/stampa",null,"Sharjah : , : Bentham Science Publishers, , 2021"]
[{"$nulls":4},"©2021"]
[null,null,"ISBN",null,"1-68108-805-3"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (225 pages)"]
[null,null,"Disciplina",null,"362.1962414"]
[null,null,"Soggetti",null,"Covid-19 vaccines"]
[{"$nulls":4},"Public policy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Prevention of COVID-19: Facts to Overcome the Myths -- Rajesh Kumar1, Mangesh Pradeep Kulkarni1, Sheetu Wadhwa1 and Soundappan Kathirvel2,* -- INTRODUCTION -- MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS -- Personal Protective Equipment (PPE) -- Head Covers -- Face Shield -- Mask -- Goggles -- Gloves -- Shoe Covers -- Gowns or Coveralls -- SANITIZATION AND DISINFECTION -- Hand Hygiene -- For Public -- Prevention of COVID-19 Among Frontline Healthcare Workers -- Cleaning of Vegetables-Fruits -- Safe Handling of Currency and Paper Documents -- Cough or Respiratory Etiquettes -- Precautions to be Taken While Coughing/Sneezing or Any Physical Contact -- Spitting or Littering in Public -- Disinfection of Public Places -- Disposal and Disinfection of PPEs -- WATER TREATMENT AND WASTE MANAGEMENT -- Management of Water and Faecal Waste -- Safety of Water Supplies -- SOCIAL MEASURES -- Physical Distancing -- Quarantine and Isolation -- Home Quarantine -- Institutional Quarantine -- Staff Guidelines -- Utility Guidelines -- Lockdown and Travel Restrictions -- Zonal Classification of the Geography -- PROPHYLAXIS FOR COVID-19 -- Dietary Recommendations for the Prevention of COVID-19 -- General Measures -- Medicinal Plant Measures/Procedures -- Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient -- REGULAR SCREENING -- PRECAUTIONS FOR TRAVEL -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF "]
[{"$nulls":4},"INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Treatment Methods for Coronavirus Disease-19 -- Kuldeep Kumar1, Sonal1, Pankaj Bhatia1, Dhandeep Singh1, Amteshwar S. Jaggi1 and Nirmal Singh1,* -- INTRODUCTION -- OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19."]
[{"$nulls":4},"Hydroxychloroquine -- HCQ in Treatment of COVID-19 -- Remdesivir -- Remdesivir in Treatment of COVID-19 -- Lopinavir/Ritonavir -- Lopinavir/Ritonavir in Treatment of COVID-19 -- Favipiravir -- Favipiravir in Treatment of COVID-19 -- Azithromycin (AZ) -- AZ in COVID-19 Treatment -- Arbidol -- Arbidol in Treatment of COVID-19 -- Ribavirin -- Ribavirin in COVID-19 Treatment -- Teicoplanin -- Teicoplanin in COVID-19 Treatment -- Ivermectin -- Ivermectin in Treatment of COVID-19 -- Nitazoxanide -- Nitazoxanide in COVID-19 Treatment -- Corticosteroids -- Corticosteroids in the Treatment of COVID-19 -- Immuno Modulating Agents-Interferons (IFN's) -- IFN's in Treatment of COVID-19 -- Monoclonal Antibody Therapy -- 80R Immunoglobulin G1 (IgGI) -- CR3014 -- Monoclonal Antibody Therapy in COVID-19 Treatment -- Tocilizumab -- Sarilumab -- Limitations and Suggestions Regarding mAb's -- Triple Therapy -- Miscellaneous Drugs -- Herbal Drugs for COVID-19 -- Glycyrrhizin -- Glycyrrhizin in COVID-19 -- Hesperetin -- Baicalin -- Scutellarin -- Plasma Therapy -- Plasma Therapy in the Treatment of COVID-19 -- Potential of Stem Cell Therapy in COVID-19 -- BCG Vaccine -- VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- AUTHORS CONTRIBUTION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Mortality -- Rimesh Pal1 and Sanjay Kumar Bhadada1,* -- INTRODUCTION -- REPRESENTING MORTALITY - MORTALITY RATE VS. CASE-FATALITY RATE -- FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE -- REPORTING COVID-19-RELATED DEATHS -- COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES -- COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS -- CAUSES OF DEATH IN COVID-19."]
[{"$nulls":4},"PARAMETERS PREDICTING MORTALITY IN COVID-19 -- Clinical Parameters -- Age -- Gender -- Symptoms -- Complications -- Comorbid Illness -- Smoking -- Secondary Infections -- Laboratory Parameters -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Long Term Complications of COVID-19 -- Ankita Sood1, Bimlesh Kumar1,*, Indu Melkani1, Archit Sood2, Pankaj Prashar1, Anamika Gautam1, Kardam Joshi3 and Dhara Patel3 -- INTRODUCTION -- LONG TERM COMPLICATIONS OF COVID-19 -- COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES -- Diabetes Mellitus (DM) -- Hematological Complications -- Cardiovascular Diseases -- Central Nervous System Complications -- Viral Encephalitis -- Infectious Toxic Encephalopathy and Cerebrovascular Disease -- Chronic Kidney Disease (CKD) -- Asthma and Respiratory Disorders -- Rheumatoid Arthritis (RA) -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Vaccine Development -- Priya Sharma1,#, Shivani Joshi1,#, Aishwarya Joshi1, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: VACCINE DEVELOPMENT -- COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM -- TYPES OF VACCINES AND THEIR CHARACTERISTICS -- Live-attenuated Virus and Inactivated Whole Virus Vaccines -- Subunit Vaccines -- Vaccines Based on Virus-like Particles (VLPs) -- Viral Vector-based "]
[{"$nulls":4},"Vaccines -- DNA Vaccines -- NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS -- Serum Albumin Strategy -- Natural Product (Plant) Based Technology -- Nanotechnology and Material Science -- mRNA Based Approaches -- ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS -- Animal Models Currently in Practice -- Humanized Mice Models -- Novel Approach of Using Zebrafish (Their Advantages) -- CURRENT STATUS OF VACCINE DEVELOPMENT."]
[{"$nulls":4},"BENCH TO BEDSIDE: OBSTACLES AND OUTCOMES -- Lessons from Previous Vaccine Development -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Future of COVID-19 Treatment -- Sahil Arora1,#, Manvendra Kumar1,#, Gaurav Joshi1,* and Raj Kumar1,* -- INTRODUCTION -- DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE -- DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE -- ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19 -- MISCELLANEOUS -- DISCUSSION AND CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover."]
[null,null,null,"Sommario/riassunto","The coronavirus disease 2019 (COVID-19) outbreak has spread throughout the globe and much time has passed since it was declared as a pandemic by the World Health Organization (WHO). COVID-19: Diagnosis and Management provides clinicians and scholars all the information on this disease in 2 volumes. Readers will find a concise and visual reference for this viral disease and will be equipped with the knowledge to assess and manage Sar-Cov-2 infection cases in clinical settings. This book is divided into two parts (I and II). Part I provides comprehensive information about 1 History of Coronaviruses, 2 Epidemiology of COVID-19, 3 Clinical presentation of this viral disease and 4 COVID-19 diagnosis. Part II covers broader topics about this communicable disease including 1 the prevention and treatment methodology, 2 mortality and long-term complications, 3 COVID-19 vaccines and future perspectives. Key Features: - Covers all the aspects of COVID-19 making this a perfect textbook for virology and medical students. -Chapter wise description and segregation of topics from pathophysiology to diagnosis and management of COVID-19. -Six chapters in the first part which focus on clinical basics of COVID-19. -Six chapters in the second part which cover broader topics for practical infection control. -Multiple tables and figures which summarize and highlight important points. -Presents a summary of the current standards for the evaluation and diagnosis of COVID-19. - Features a detailed list of references, abbreviations, and symbols. This book is an essential textbook reference for medical students, scientists (virologists, pulmonologists) and public health officials who are required to understand COVDI-19 diagnosis and management as part of their clinical training or professional work."]